TOX Monoclonal Antibody (TXRX10), PE, eBioscience™, Invitrogen™

Description

• Description: This TXRX10 monoclonal antibody reacts with human and mouse TOX, which is also known as Thymocyte selection-associated HMG box protein
• This DNA-binding nuclear factor is expressed in thymocytes, T lymphocytes, NK cells, and lymphoid tissue-inducer (LTi) cells
• TOX expression in thymocytes is upregulated during beta-selection and positive selection
• Studies using Tox knockout mice have demonstrated a critical role for TOX in CD4+ T cell development as a regulator of the CD4loCD8lo to CD4+CD8lo transition
• Moreover, TOX has been shown to be involved in the development of NK and LTi cells
• While its regulation remains unclear, TOX expression has been shown to be induced by calcineurin-mediated TCR signaling in thymocytes during positive selection
• Applications Reported: This TXRX10 antibody has been reported for use in intracellular staining followed by flow cytometric analysis
• Applications Tested: This TXRX10 antibody has been tested intracellular flow cytometric analysis of mouse thymocytes using the Foxp3 Buffers (cat
• 00-5521) and protocol
• This can be used at less than or equal to 0.5 μg per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest
• TOX (thymocyte selection-associated high mobility group (HMG) box protein) is a member of the HMG box family of DNA-binding proteins and likely plays a role in the regulation of T-cell development
• It is a 526 amino acid nuclear protein and the expression of TOX is upregulated by pre-T cell receptor (pre-TCR) and TCR activation in immature thymocytes
• TOX-mediated positive selection is associated with up-regulation of RUNX3 and is calcineurin dependent
• TOX-dependent transition to the CD4+CD8 stage is required for development of class II major histocompatibility complex-specific T cells.